Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Tolerability of Multiple Ascending Doses of LY2140023 in Subjects With Schizophrenia.

Next Previous
Trial Profile

Safety and Tolerability of Multiple Ascending Doses of LY2140023 in Subjects With Schizophrenia.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 16 Sep 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pomaglumetad methionil (Primary) ; Aripiprazole
  • Indications Schizophrenia
  • Focus Adverse reactions
  • Sponsors Denovo Biopharma

Most Recent Events

  • 09 Aug 2012 Actual end date Mar 2012 added as reported by ClinicalTrials.gov.
  • 27 Mar 2012 Planned end date changed from 1 Mar 2012 to 1 Jul 2012 as reported by ClinicalTrials.gov.
  • 01 Mar 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top